{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T02:17:39Z","timestamp":1751422659071,"version":"3.37.3"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T00:00:00Z","timestamp":1699315200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["#81502108","#81974438, #82173069"],"award-info":[{"award-number":["#81502108","#81974438, #82173069"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Cholangiocarcinoma (CCA) refers to a collection of malignant tumors that develop from the biliary epithelium. Extensive clinical evidence and epidemiological observations indicate a concerning increase in both the incidence and mortality rates of CCA. Surgical resection is currently the sole available cure for CCA. However, it is unfortunate that only a fraction of patients has access to surgery at the time of diagnosis. Moreover, there is a high incidence of cancer recurrence after resection, and systemic treatments have limited efficacy. Therefore, the identification of novel biomarkers for CCA-targeted molecular therapy remains a crucial task in oncology research.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Our study demonstrated that low expression of RSPO3 was associated with poorer survival rates in patients with CCA. We found that the RSPO3 promoter DNA was hypermethylated in CCA, which was correlated with the low expression of RSPO3. The expression of RSPO3 was influenced by the balance between the DNA methyltransferase DNMT3a and the DNA demethylase TET1 in CCA. In vitro and in vivo experiments showed that targeting RSPO3 promoter DNA methylation using dCas9DNMT3a promoted tumorigenicity of CCA, while targeted RSPO3 promoter DNA demethylation using dCas9TET1CD inhibited CCA tumorigenicity. Additionally, in our primary CCA model, knockdown of Rspo3 promoted CCA progression, whereas overexpression of Rspo3 inhibited CCA progression.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our findings suggest that increased methylation and decreased expression of RSPO3 may indicate a poor prognosis in CCA. Restoring RSPO3 expression by targeting promoter DNA demethylation could offer insights for precise treatment of CCA.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13148-023-01592-9","type":"journal-article","created":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T03:01:54Z","timestamp":1699326114000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Upregulation of RSPO3 via targeted promoter DNA demethylation inhibits the progression of cholangiocarcinoma"],"prefix":"10.1186","volume":"15","author":[{"given":"Guanhua","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Da","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fei","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenzheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junsheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,11,7]]},"reference":[{"issue":"9","key":"1592_CR1","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, Cardinale V, Carpino G, Andersen JB, Braconi C, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"1","key":"1592_CR2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","volume":"72","author":"O Clements","year":"2020","unstructured":"Clements O, Eliahoo J, Kim JU, Taylor-Robinson SD, Khan SA. Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis. J Hepatol. 2020;72(1):95\u2013103.","journal-title":"J Hepatol"},{"issue":"Suppl 1","key":"1592_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1111\/liv.14101","volume":"39","author":"JM Banales","year":"2019","unstructured":"Banales JM, Cardinale V, Macias RIR, Andersen JB, Braconi C, Carpino G, Alvaro D, Calvisi DF. Cholangiocarcinoma: state-of-the-art knowledge and challenges. Liver Int. 2019;39(Suppl 1):5\u20136.","journal-title":"Liver Int"},{"issue":"2","key":"1592_CR4","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1080\/13651820801992641","volume":"10","author":"SA Khan","year":"2008","unstructured":"Khan SA, Toledano MB, Taylor-Robinson SD. Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB (Oxford). 2008;10(2):77\u201382.","journal-title":"HPB (Oxford)"},{"issue":"Suppl 1","key":"1592_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","volume":"39","author":"SA Khan","year":"2019","unstructured":"Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19\u201331.","journal-title":"Liver Int"},{"issue":"8","key":"1592_CR6","first-page":"1669","volume":"71","author":"RIR Macias","year":"2022","unstructured":"Macias RIR, Cardinale V, Kendall TJ, Avila MA, Guido M, Coulouarn C, Braconi C, Frampton AE, Bridgewater J, Overi D, et al. Clinical relevance of biomarkers in cholangiocarcinoma: critical revision and future directions. Gut. 2022;71(8):1669\u201383.","journal-title":"Gut"},{"issue":"6","key":"1592_CR7","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1159\/000452921","volume":"32","author":"A Radtke","year":"2016","unstructured":"Radtke A, K\u00f6nigsrainer A. Surgical therapy of cholangiocarcinoma. Visc Med. 2016;32(6):422\u20136.","journal-title":"Visc Med"},{"issue":"10272","key":"1592_CR8","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","volume":"397","author":"JW Valle","year":"2021","unstructured":"Valle JW, Kelley RK, Nervi B, Oh DY, Zhu AX. Biliary tract cancer. Lancet (London, England). 2021;397(10272):428\u201344.","journal-title":"Lancet (London, England)"},{"issue":"3","key":"1592_CR9","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.devcel.2011.01.006","volume":"20","author":"B Ohkawara","year":"2011","unstructured":"Ohkawara B, Glinka A, Niehrs C. Rspo3 binds syndecan 4 and induces Wnt\/PCP signaling via clathrin-mediated endocytosis to promote morphogenesis. Dev Cell. 2011;20(3):303\u201314.","journal-title":"Dev Cell"},{"issue":"3","key":"1592_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.imbio.2023.152336","volume":"228","author":"N Ning","year":"2023","unstructured":"Ning N, Wang Q, Li J, Liu B, Chen G, Hui J, An L. Amniotic fluid stem cell attenuated necrotizing enterocolitis progression by promoting Rspo3\/AMPK\u03b1 axis. Immunobiology. 2023;228(3): 152336.","journal-title":"Immunobiology"},{"key":"1592_CR11","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.84171","volume":"11","author":"K Nagano","year":"2022","unstructured":"Nagano K, Yamana K, Saito H, Kiviranta R, Pedroni AC, Raval D, Niehrs C, Gori F, Baron R. R-spondin 3 deletion induces Erk phosphorylation to enhance Wnt signaling and promote bone formation in the appendicular skeleton. Elife. 2022;11: e84171.","journal-title":"Elife"},{"issue":"1","key":"1592_CR12","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1080\/07853890.2023.2166981","volume":"55","author":"Z He","year":"2023","unstructured":"He Z, Zhang J, Ma J, Zhao L, Jin X, Li H. R-spondin family biology and emerging linkages to cancer. Ann Med. 2023;55(1):428\u201346.","journal-title":"Ann Med"},{"issue":"2","key":"1592_CR13","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1093\/carcin\/bgy140","volume":"40","author":"Z Chen","year":"2019","unstructured":"Chen Z, Zhou L, Chen L, Xiong M, Kazobinka G, Pang Z, Hou T. RSPO3 promotes the aggressiveness of bladder cancer via Wnt\/\u03b2-catenin and Hedgehog signaling pathways. Carcinogenesis. 2019;40(2):360\u20139.","journal-title":"Carcinogenesis"},{"issue":"3","key":"1592_CR14","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/path.5999","volume":"258","author":"EJ Ter Steege","year":"2022","unstructured":"Ter Steege EJ, Boer M, Timmer NC, Ammerlaan CM, Song JY, Derksen PW, Hilkens J, Bakker ER. R-spondin-3 is an oncogenic driver of poorly differentiated invasive breast cancer. J Pathol. 2022;258(3):289\u201399.","journal-title":"J Pathol"},{"issue":"21","key":"1592_CR15","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.21037\/atm-20-3731","volume":"8","author":"H Gu","year":"2020","unstructured":"Gu H, Tu H, Liu L, Liu T, Liu Z, Zhang W, Liu J. RSPO3 is a marker candidate for predicting tumor aggressiveness in ovarian cancer. Ann Transl Med. 2020;8(21):1351.","journal-title":"Ann Transl Med"},{"issue":"47","key":"1592_CR16","doi-asserted-by":"publisher","first-page":"6469","DOI":"10.1038\/s41388-021-02059-y","volume":"40","author":"EJ Ter Steege","year":"2021","unstructured":"Ter Steege EJ, Bakker ERM. The role of R-spondin proteins in cancer biology. Oncogene. 2021;40(47):6469\u201378.","journal-title":"Oncogene"},{"issue":"12","key":"1592_CR17","doi-asserted-by":"publisher","first-page":"3142","DOI":"10.1158\/2159-8290.CD-20-0833","volume":"11","author":"Y Tang","year":"2021","unstructured":"Tang Y, Xu Q, Hu L, Yan X, Feng X, Yokota A, Wang W, Zhan D, Krishnamurthy D, Ochayon DE, et al. Tumor microenvironment-derived R-spondins enhance antitumor immunity to suppress tumor growth and sensitize for immune checkpoint blockade therapy. Cancer Discov. 2021;11(12):3142\u201357.","journal-title":"Cancer Discov"},{"issue":"1","key":"1592_CR18","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1186\/s12967-019-1878-3","volume":"17","author":"A Mesci","year":"2019","unstructured":"Mesci A, Lucien F, Huang X, Wang EH, Shin D, Meringer M, Hoey C, Ray J, Boutros PC, Leong HS, et al. RSPO3 is a prognostic biomarker and mediator of invasiveness in prostate cancer. J Transl Med. 2019;17(1):125.","journal-title":"J Transl Med"},{"issue":"36","key":"1592_CR19","doi-asserted-by":"publisher","first-page":"4692","DOI":"10.1038\/onc.2014.417","volume":"34","author":"X Gong","year":"2015","unstructured":"Gong X, Yi J, Carmon KS, Crumbley CA, Xiong W, Thomas A, Fan X, Guo S, An Z, Chang JT, et al. Aberrant RSPO3-LGR4 signaling in Keap1-deficient lung adenocarcinomas promotes tumor aggressiveness. Oncogene. 2015;34(36):4692\u2013701.","journal-title":"Oncogene"},{"key":"1592_CR20","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.916725","volume":"10","author":"X Man","year":"2022","unstructured":"Man X, Li Q, Wang B, Zhang H, Zhang S, Li Z. DNMT3A and DNMT3B in breast tumorigenesis and potential therapy. Front Cell Dev Biol. 2022;10: 916725.","journal-title":"Front Cell Dev Biol"},{"key":"1592_CR21","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.ebiom.2016.10.028","volume":"13","author":"H Li","year":"2016","unstructured":"Li H, Li W, Liu S, Zong S, Wang W, Ren J, Li Q, Hou F, Shi Q. DNMT1, DNMT3A and DNMT3B polymorphisms associated with gastric cancer risk: a systematic review and meta-analysis. EBioMedicine. 2016;13:125\u201331.","journal-title":"EBioMedicine"},{"issue":"21","key":"1592_CR22","doi-asserted-by":"publisher","first-page":"18347","DOI":"10.1074\/jbc.R110.205286","volume":"286","author":"ZX Chen","year":"2011","unstructured":"Chen ZX, Riggs AD. DNA methylation and demethylation in mammals. J Biol Chem. 2011;286(21):18347\u201353.","journal-title":"J Biol Chem"},{"issue":"7","key":"1592_CR23","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s00018-022-04396-x","volume":"79","author":"K Joshi","year":"2022","unstructured":"Joshi K, Liu S, Breslin SJP, Zhang J. Mechanisms that regulate the activities of TET proteins. Cell Mol Life Sci. 2022;79(7):363.","journal-title":"Cell Mol Life Sci"},{"issue":"1","key":"1592_CR24","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13148-022-01329-0","volume":"14","author":"T Aumer","year":"2022","unstructured":"Aumer T, Gremmelmaier CB, Runtsch LS, Pforr JC, Ye\u015filta\u00e7 GN, Kaiser S, Traube FR. Comprehensive comparison between azacytidine and decitabine treatment in an acute myeloid leukemia cell line. Clin Epigenet. 2022;14(1):113.","journal-title":"Clin Epigenet"},{"key":"1592_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.matbio.2014.06.003","volume":"37","author":"MN Knight","year":"2014","unstructured":"Knight MN, Hankenson KD. R-spondins: novel matricellular regulators of the skeleton. Matrix Biol J Int Soc Matrix Biol. 2014;37:157\u201361.","journal-title":"Matrix Biol J Int Soc Matrix Biol"},{"issue":"1","key":"1592_CR26","doi-asserted-by":"publisher","first-page":"13020","DOI":"10.1038\/s41598-022-16640-2","volume":"12","author":"Y Mita","year":"2022","unstructured":"Mita Y, Zhu H, Furuichi Y, Hamaguchi H, Manabe Y, Fujii NL. R-spondin3 is a myokine that differentiates myoblasts to type I fibres. Sci Rep. 2022;12(1):13020.","journal-title":"Sci Rep"},{"issue":"2","key":"1592_CR27","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.ccell.2020.05.014","volume":"38","author":"B Salik","year":"2020","unstructured":"Salik B, Yi H, Hassan N, Santiappillai N, Vick B, Connerty P, Duly A, Trahair T, Woo AJ, Beck D, et al. Targeting RSPO3-LGR4 signaling for leukemia stem cell eradication in acute myeloid leukemia. Cancer Cell. 2020;38(2):263-278.e266.","journal-title":"Cancer Cell"},{"issue":"1","key":"1592_CR28","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1038\/s41467-020-16592-z","volume":"11","author":"NY Loh","year":"2020","unstructured":"Loh NY, Minchin JEN, Pinnick KE, Verma M, Todor\u010devi\u0107 M, Denton N, Moustafa JE, Kemp JP, Gregson CL, Evans DM, et al. RSPO3 impacts body fat distribution and regulates adipose cell biology in vitro. Nat Commun. 2020;11(1):2797.","journal-title":"Nat Commun"},{"issue":"1","key":"1592_CR29","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s13148-019-0675-4","volume":"11","author":"A Roberti","year":"2019","unstructured":"Roberti A, Valdes AF, Torrecillas R, Fraga MF, Fernandez AF. Epigenetics in cancer therapy and nanomedicine. Clin Epigenet. 2019;11(1):81.","journal-title":"Clin Epigenet"},{"issue":"1","key":"1592_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13148-023-01425-9","volume":"15","author":"B Li","year":"2023","unstructured":"Li B, Ren B, Ma G, Cai F, Wang P, Zeng Y, Liu Y, Zhang L, Yang Y, Liang H, et al. Inactivation of ZSCAN18 by promoter hypermethylation drives the proliferation via attenuating TP53INP2-mediated autophagy in gastric cancer cells. Clin Epigenet. 2023;15(1):10.","journal-title":"Clin Epigenet"},{"issue":"2","key":"1592_CR31","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s12032-022-01943-1","volume":"40","author":"S Bhootra","year":"2023","unstructured":"Bhootra S, Jill N, Shanmugam G, Rakshit S, Sarkar K. DNA methylation and cancer: transcriptional regulation, prognostic, and therapeutic perspective. Med Oncol. 2023;40(2):71.","journal-title":"Med Oncol"},{"issue":"13","key":"1592_CR32","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1007\/s40265-020-01389-7","volume":"80","author":"S Dhillon","year":"2020","unstructured":"Dhillon S. Decitabine\/cedazuridine: first approval. Drugs. 2020;80(13):1373\u20138.","journal-title":"Drugs"},{"issue":"21","key":"1592_CR33","doi-asserted-by":"publisher","first-page":"1998","DOI":"10.1056\/NEJMoa2119771","volume":"386","author":"YC Liu","year":"2022","unstructured":"Liu YC, Kwon J, Fabiani E, Xiao Z, Liu YV, Follo MY, Liu J, Huang H, Gao C, Liu J, et al. Demethylation and up-regulation of an oncogene after hypomethylating therapy. N Engl J Med. 2022;386(21):1998\u20132010.","journal-title":"N Engl J Med"},{"issue":"6","key":"1592_CR34","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/s43018-022-00361-6","volume":"3","author":"F Na","year":"2022","unstructured":"Na F, Pan X, Chen J, Chen X, Wang M, Chi P, You L, Zhang L, Zhong A, Zhao L, et al. KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogramming. Nat Cancer. 2022;3(6):753\u201367.","journal-title":"Nat Cancer"},{"issue":"8","key":"1592_CR35","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1038\/s41588-022-01119-7","volume":"54","author":"BK Wu","year":"2022","unstructured":"Wu BK, Mei SC, Chen EH, Zheng Y, Pan D. YAP induces an oncogenic transcriptional program through TET1-mediated epigenetic remodeling in liver growth and tumorigenesis. Nat Genet. 2022;54(8):1202\u201313.","journal-title":"Nat Genet"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-023-01592-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-023-01592-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-023-01592-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T03:02:00Z","timestamp":1699326120000},"score":1,"resource":{"primary":{"URL":"https:\/\/clinicalepigeneticsjournal.biomedcentral.com\/articles\/10.1186\/s13148-023-01592-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,7]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1592"],"URL":"https:\/\/doi.org\/10.1186\/s13148-023-01592-9","relation":{},"ISSN":["1868-7083"],"issn-type":[{"type":"electronic","value":"1868-7083"}],"subject":[],"published":{"date-parts":[[2023,11,7]]},"assertion":[{"value":"7 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Animal Ethics Committee of Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. Animal care and experiments were conducted in compliance with Institutional Animal Care and Use Committee and NIH guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent to publish has been obtained from all authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"177"}}